Isofol presents conclusions from the in-depth analysis of the AGENT study

Gothenburg, Sweden, July 4, 2023 – Isofol Medical AB (publ) today presents the conclusions from the company’s in-depth analysis of data from the Phase III study AGENT. The results from the analysis support the hypothesis that a different dose and administration regimen has the potential to improve the efficacy of the company’s drug candidate arfolitixorin. Isofol has therefore decided to continue the development of arfolitixorin and is intensifying preparations for a possible start of a minor clinical study.

Changes in the board at Isofol Medical AB (publ)

Gothenburg, Sweden, June 7, 2023 – Isofol Medical AB (publ) announces today that its Board of Directors has appointed Anders Edvell as a co-opted member of the Board. This is following the resignation of Jan-Eric Österlund, who today has decided to resign as Board Director and instead will take a new role as senior advisor to the company.

Isofol initiates preclinical evaluation of arfolitixorin with Oncosyne AS

Gothenburg, Sweden, April 28, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has initiated a preclinical research collaboration with the Norwegian biotech company Oncosyne AS, to evaluate the effect of the drug candidate arfolitixorin in different doses combined with the cancer drug 5-FU, among others. This is an important step in the company´s previously communicated strategy to re-evaluate possible future tracks for arfolitixorin and to maximize the opportunities to take the drug candidate further toward potential market approval.

Scroll to Top